Literature DB >> 25065492

2-Alkyloxazoles as potent and selective PI4KIIIβ inhibitors demonstrating inhibition of HCV replication.

Erin P Keaney1, Michael Connolly2, Markus Dobler2, Rajeshri Karki2, Ayako Honda2, Samantha Sokup2, Subramanian Karur2, Shawn Britt2, Anup Patnaik2, Prakash Raman2, Lawrence G Hamann2, Brigitte Wiedmann3, Matthew J LaMarche2.   

Abstract

Synthesis and SAR of 2-alkyloxazoles as class III phosphatidylinositol-4-kinase beta (PI4KIIIβ) inhibitors is described. These compounds demonstrate that inhibition of PI4KIIIβ leads to potent inhibition of HCV replication as observed in genotype (GT) 1a and 1b replicon and GT2a JFH1 virus assays in vitro.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HCV; PI4K

Mesh：

Substances：

Year:  2014        PMID： 25065492     DOI： 10.1016/j.bmcl.2014.07.015

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  7 in total

1.  Structural elements that govern Sec14-like PITP sensitivities to potent small molecule inhibitors.

Authors:  Danish Khan; Kaitlyn R McGrath; Oleksandra Dorosheva; Vytas A Bankaitis; Ashutosh Tripathi
Journal:  J Lipid Res       Date:  2016-02-26       Impact factor: 5.922

2.  Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ.

Authors:  Florentine U Rutaganira; Melissa L Fowler; Jacob A McPhail; Michael A Gelman; Khanh Nguyen; Anming Xiong; Gillian L Dornan; Brandon Tavshanjian; Jeffrey S Glenn; Kevan M Shokat; John E Burke
Journal:  J Med Chem       Date:  2016-02-26       Impact factor: 7.446

3.  Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition.

Authors:  Yong Wah Tan; Wan Keat Yam; Rachel Jia Wen Kooi; Jacob Westman; Gustav Arbrandt; Justin Jang Hann Chu
Journal:  Sci Rep       Date:  2021-05-06       Impact factor: 4.379

4.  Novel phosphatidylinositol 4-kinases III beta (PI4KIIIβ) inhibitors discovered by virtual screening using free energy models.

Authors:  Natalie M Colodette; Lucas S Franco; Rodolfo C Maia; Harold H Fokoue; Carlos Mauricio R Sant'Anna; Eliezer J Barreiro
Journal:  J Comput Aided Mol Des       Date:  2020-06-30       Impact factor: 3.686

Review 5.  Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection.

Authors:  Mirjam B Zeisel; Emilie Crouchet; Thomas F Baumert; Catherine Schuster
Journal:  Viruses       Date:  2015-11-02       Impact factor: 5.048

6.  Structural insights and in vitro reconstitution of membrane targeting and activation of human PI4KB by the ACBD3 protein.

Authors:  Martin Klima; Dániel J Tóth; Rozalie Hexnerova; Adriana Baumlova; Dominika Chalupska; Jan Tykvart; Lenka Rezabkova; Nivedita Sengupta; Petr Man; Anna Dubankova; Jana Humpolickova; Radim Nencka; Vaclav Veverka; Tamas Balla; Evzen Boura
Journal:  Sci Rep       Date:  2016-03-24       Impact factor: 4.379

7.  Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors.

Authors:  Michal Šála; Martin Kögler; Pavla Plačková; Ivana Mejdrová; Hubert Hřebabecký; Eliška Procházková; Dmytro Strunin; Gary Lee; Gabriel Birkus; Jan Weber; Helena Mertlíková-Kaiserová; Radim Nencka
Journal:  Bioorg Med Chem Lett       Date:  2016-04-05       Impact factor: 2.823
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.